Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation
- 30 September 2006
- journal article
- Published by Elsevier in Microvascular Research
- Vol. 72 (1-2), 3-11
- https://doi.org/10.1016/j.mvr.2006.04.004
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (DE00470, DE12322, DE015830)
This publication has 49 references indexed in Scilit:
- Opioid MetabolitesJournal of Pain and Symptom Management, 2005
- Tolerability, Gut Effects, and Pharmacokinetics of Methylnaltrexone Following Repeated Intravenous Administration in HumansThe Journal of Clinical Pharmacology, 2005
- Conditional ROCK Activation In vivo Induces Tumor Cell Dissemination and AngiogenesisCancer Research, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- CD44v10 interaction with Rho‐kinase (ROK) activates inositol 1,4,5‐triphosphate (IP3) receptor‐mediated Ca2+ signaling during hyaluronan (HA)‐induced endothelial cell migrationCell Motility, 2002
- Targetting VEGF in anti-angiogenic and anti-tumour therapy: Where are we now?International Journal of Experimental Pathology, 2002
- Morphine-6-GlucuronideClinical Pharmacokinetics, 2001
- The Role of Rho in G Protein-Coupled Receptor Signal TransductionAnnual Review of Pharmacology and Toxicology, 2000
- Peak Plasma Concentrations After Oral Morphine: A Systematic ReviewJournal of Pain and Symptom Management, 1998
- Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor AngiogenesisAmerican Journal of Reproductive Immunology, 1992